latest news releases from the newsroom
SuperStock Signs Exclusive Image Licensing Agreement with the San Diego Zoo
NEW YORK, Nov. 19, 2003 (PRIMEZONE) -- a21, Inc. ("a21:) (OTCBB:ATWO), a digital business partner for top-tier photographers and image archives, announced today that SuperStock, Inc. has signed an exclusive image licensing agreement with the Zoological Society of San Diego, a not-for-profit organization that operates both the San Diego Zoo and the San Diego Zoo's Wild Animal Park. Beginning in early 2004, more than 8,500 images of exotic animals and plant life will be available for worldwide licensing through SuperStock (http://www.superstock.com).
Capital Research Group, Inc
TheSUBWAY.com Announces Its Morning Stock Focus List for Wednesday, November 19, 2003: WTSW, NXTL, EMC, JNPR
WESTON, Fla., Nov. 19, 2003 (PRIMEZONE) -- TheSUBWAY.com announces Worldtradeshow.com Inc. (OTCBB:WTSW) to its Stock Focus List. WTSW is new to TheSUBWAY.com, and we expect great things from this stock! Watch this company; it has announced great news, and we think it is due to make a move in the near term! Other stocks highlighted include:
Amersham Biosciences Updates CodeLink Informatics Solution to Provide Complete Data Management
BUCKINGHAMSHIRE, U.K. and PISCATAWAY, N.J., Nov. 19, 2003 (PRIMEZONE) -- Amersham Biosciences, the life sciences business of Amersham (LSE:AHM) (NYSE:AHM) (OSE:AHM), has enhanced its CodeLink(TM) Informatics Solution to help scientists to improve productivity further by streamlining data extraction, acquisition and management processes in their gene expression experiments. The suite of tools includes CodeLink Expression Analysis software, new workflows added to the Scierra(TM) Microarray Laboratory Workflow System (LWS) and compatibility with Scierra LWS DiscoveryHub(TM) platform.
MSSI-TeleScience International Inc.
MSSI -- TeleScience International Announces Federal Supply Schedule (FSS) Contract
VIENNA, Va., Nov. 19, 2003 (PRIMEZONE) -- MSSI-TeleScience International Inc. (OTCBB:MSSI), a provider of medical personnel, homeland security and technology services to state and federal government agencies, announced today that its Medical Staffing Division has concluded the first quarter in which it inaugurated contract services under its Federal Supply Schedule contract with the federal government's National Acquisition Center. The contract, otherwise known as the FSS Contract, allows all offices of the federal government to negotiate single-source contracts directly with the Company, and also puts the Company on a preferred "short list" of contractors for medical staffing opportunities. The FSS contract is circulated widely among government contracting offices. The result is that these federal government customers contact the Company continuously, allowing it to pick and choose among the most attractive business opportunities, thus greatly simplifying its marketing efforts.
WebBox Exceeds Income Expectations For October, 2003
SUWANEE, Ga., Nov. 19, 2003, Nov. 19, 2003 (PRIMEZONE) -- Brandmakers, Inc. (OTCBB:BMKSE) announced that their Internet Division, MailStart-WebBox, exceeded income expectations for October, 2003 and continues to be profitable with exceptionally low overhead. The division offers free email service on www.mailstart.com limited to once per week usage to encourage sign ups to the WebBox subscription service, www.webbox.com . The WebBox annual subscription fee was increased in September, 2003 to $18 from $15, considered to be quite a bargain at just $1.50 per month.
Dobson Communications Corporation
Dobson Communications Approved for Trading on Nasdaq National Market
OKLAHOMA CITY, Nov. 19, 2003 (PRIMEZONE) -- Dobson Communications Corporation (Nasdaq:DCEL) today announced that its Class A common stock has been approved for trading on the Nasdaq National Market. The Company expects the move from the Nasdaq SmallCap to the Nasdaq National Market will be effective at the open of regular trading today. Dobson's Class A common stock will continue to trade under the symbol DCEL.
Duke University Study Abstract Shows Significantly Lower Incidence of Major Adverse Cardiac Events Following Percutaneous Coronary Intervention Using Visipaque Compared to Isovue
BUCKINGHAMSHIRE, U.K., Nov. 19, 2003 (PRIMEZONE) -- The findings of a Duke University study abstract that were reported at the American Heart Association meeting November 9-12 in Orlando, Florida, indicated that the use of Visipaque(TM) (iodixanol), a diagnostic pharmaceutical produced by Amersham plc (LSEAHM) (NYSE:AHM) (OSE:AHM), was found to have a significantly lower incidence of in-hospital major adverse cardiac events (MACE) compared to Isovue(R) (iopamidol) in patients who undergo an interventional therapeutic cardiac procedure.Visipaque(TM) is a nonionic, isosmolar contrast medium used to provide enhanced X-ray images of soft tissues, primarily blood vessels and organs, for the diagnosis of many common diseases.